Generate Biomedicines, Inc. (GENB)

Generate Biomedicines Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024
Cash & Equivalents	160.58	121.65	176.27
Short-Term Investments	356.07	99.85	217.36
Cash & Short-Term Investments	516.64	221.5	393.63
Cash Growth	31.25%	-43.73%	-
Accounts Receivable	-	-	0.31
Other Current Assets	18.75	12.87	13.56
Total Current Assets	535.39	234.37	407.49
Net Property, Plant & Equipment	85.6	89.01	101.07
Other Long-Term Assets	4.75	6.81	9.7
Total Assets	625.74	330.18	518.26
Accounts Payable	7.62	3.84	5.67
Accrued Expenses	19.27	42.16	21.77
Current Portion of Leases	14.26	15.01	16.72
Unearned Revenue	17.24	21.19	42.43
Other Current Liabilities	-	-	0.05
Total Current Liabilities	58.39	82.2	86.63
Long-Term Leases	51.31	53.52	60.26
Other Long-Term Liabilities	1.24	5.83	16.62
Total Long-Term Liabilities	52.55	59.35	76.87
Total Liabilities	110.94	141.55	163.5
Common Stock	0.13	0.03	0.03
Additional Paid-in Capital	1,252	60.19	38.47
Accumulated Other Comprehensive Income	0.02	0.11	0.12
Retained Earnings	-737.74	-676.29	-473.14
Total Common Shareholders' Equity	514.8	-615.97	-434.52
Minority Interest	-	804.59	789.28
Shareholders' Equity	514.8	188.63	354.76
Total Liabilities & Equity	625.74	330.18	518.26
Total Debt	65.57	68.53	76.97
Net Cash (Debt)	451.07	152.97	316.66
Net Cash Growth	194.87%	-51.69%	-
Net Cash Per Share	3.52	4.64	9.87
Book Value	514.8	-615.97	-434.52
Book Value Per Share	4.02	-18.68	-13.54
Tangible Book Value	514.8	-615.97	-434.52
Tangible Book Value Per Share	4.02	-18.68	-13.54

Updated May 7, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q